Using a 3D human neural cell culture model, researchers showed that this hormone leads to the production of the enzyme neprilysin, which decreases the presence of amyloid beta, according to the study, which was published Sept. 8 in the journal Neuron.
The findings could reveal “a new target pathway for therapies aimed at the prevention and treatment of Alzheimer’s disease,” Rudolph Tanzi, PhD, a senior author of the study and the director of the Genetics and Aging Research Unit, said in a press release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
